On Saturday, Trump said he would impose additional sanctions against Iran in a bid to prevent the country obtaining nuclear weapons.World Politicsread more
The major indexes have stretched to all-time highs and are riding one of their best first halves in decades.Trading Nationread more
Tensions between the U.S. and Iran will likely escalate in the near future, a former adviser to the Iranian government said on Monday.Energyread more
Millennial stocks are looking fly this month, and one name could be on the verge of exploding in the next year.Trading Nationread more
Chinese vice commerce minister said Monday that Beijing would like the U.S. to cancel "inappropriate" actions against Chinese companies.China Economyread more
Eldorado Resorts has agreed to merge with Caesars Entertainment in a cash and stock deal that values its peer at about $17.3 billion including debt.Casinos and Gamingread more
A decisive win for Turkey's main opposition party in a re-run of a mayoral election in Istanbul this weekend has prompted hopes for economic and political change.Europe Politicsread more
Sixteen Asia Pacific countries have been negotiating the Regional Comprehensive Economic Partnership since 2013, with India's reluctance to open up its markets a major...Asia Economyread more
The secretary of State said he was traveling to Saudi Arabia and the United Arab Emirates to make sure that the U.S. is "strategically aligned" with its allies.Politicsread more
Experts say Facebook's cryptocurrency project Libra has been a catalyst for the price of bitcoin going higher.Technologyread more
Goldman Sachs helped state firm 1MDB to raise $6.5 billion in 2012 and 2013, and collected higher-than-typical fees of $600 million for the deals.Financeread more
Despite engaging in $100 billion of dealmaking in the last year, Actavis CEO Brent Saunders does not see mergers and acquisitions as the company's primary strategy.
"You have to be committed to R&D and innovation to be successful long term in our industry. However, you have to do things that you have a comparable advantage doing," he told CNBC's "Squawk Box" on Friday. "So for us, we didn't have an advantage in discovery."
The drugmaker's recent deals have included a $66 billion purchase of Allergan in November and a $28 billion buyout of Forest Labs in July. During its $100 billion dealmaking spree, Actavis has not invented new products.
The company did not plan to be so hungry for deals, said Saunders, asserting that Allergan was not part of its strategic plan.
"It was put in play through a hostile situation, and we were opportunistic because it was available and we had a relationship and it fit strategically with what we were trying to do and we could get it at a fair price," he said.
The deal ended a six-month-long hostile takeover bid that pitted Allergan against activist investor Bill Ackman and Valeant Pharmaceuticals.
Over the last 10 years, the return on investment in pharmaceutical research and development has not been great and is probably below the cost of capital, said Fred Hassan, managing director at private equity firm Warburg Pincus.
He told "Squawk Box" that raises the question of whether now is the time to invest in R&D or to be more watchful and opportunistic.
Saunders said it is indeed a time to invest, but he noted that overcapacity in the commercial and R&D sides of the business is creating turmoil.
As the customers, hospitals, retailers and wholesalers consolidate, the industry needs to to take some slack out of the market, he said. So while eight drug companies may be targeting the same molecules or methods of action, perhaps only two or three should be doing so, he added.
"That's how you get 'me too' drugs. There's a lot of money spent unnecessarily because there's so much capacity in the market," Saunders said.
—CNBC's Ahuja Maneet contributed reporting to this story.